tradingkey.logo

Protagonist Therapeutics Inc <PTGX.OQ> expected to post a loss of 17 cents a share - Earnings Preview

ReutersMay 5, 2025 9:08 PM
  • Protagonist Therapeutics Inc PTGX.OQ PTGX.O is expected to show a fall in quarterly revenue when it reports results on May 5 (estimated) for the period ending March 31 2025

  • The Newark California California-based company is expected to report a 88.1% decrease in revenue to $30.444 million from $254.95 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Protagonist Therapeutics Inc is for a loss of 17 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had fallen by about 12.2% in the last three months. ​

  • Wall Street's median 12-month price target for Protagonist Therapeutics Inc is $70.00​, above​ its last closing price of $45.51. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

0.63

0.32

1.98

Beat

516.6

Sep. 30 2024

-0.58

-0.61

-0.54

Beat

11.1

Jun. 30 2024

-0.57

-0.60

-0.50

Beat

16.9​

Mar. 31 2024

0.54

1.19

3.26

Beat

173.1

​​Dec. 31 2023

0.03

-0.03

0.44

Beat

1,425.3

Sep. 30 2023

-0.70

-0.69

-0.58

Beat

16.4​

Jun. 30 2023

-0.65

-0.65

-0.68

Missed

-5

Mar. 31 2023

-0.77

-0.73

-0.67

Beat

7.8

This summary was machine generated May 5 at 21:08 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI